ImmuCell (FRA:IUL) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IUL ImmuCell Corp FRA:IUL
55 GF Score
Price €8.30
GF Value €5.66
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:IUL
55GF Score
ImmuCell Corp FRA:IUL
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ImmuCell (FRA:IUL) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of €8.30 is trading 46.6% above its estimated GF Value™ of €5.66. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for FRA:IUL:

  • Interest Received:
  • GF Value™: €5.66 vs. price of €8.30 (46.6% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:IUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ImmuCell Business Description

Other Exchanges ICCC:USA
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
55GF Score

Get the complete analysis for FRA:IUL

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.30
Price
€5.66
GF Value